Download PDF
Dtsch Med Wochenschr 2004; 129(20): 1120-1124
DOI: 10.1055/s-2004-824859
Originalien
Endokrinologie/Infektiologie
© Georg Thieme Verlag Stuttgart · New York

Autoantikörper gegen Inselzellantigene und Diabetes mellitus Typ 1 unter Interferon alpha-Kombinationstherapie

Islet-cell antibodies and type 1 diabetes after treatment with interferon-alphaM. Schories1 , T. Peters2 , J. Rasenack1 , M. Reincke1
  • 1Abteilung Innere Medizin II, Gastroenterologie, Hepatologie, Endokrinologie und Infektiologie, Albert-Ludwigs-Universität Freiburg
  • 2Claraspital, Basel
Further Information

Publication History

eingereicht: 27.1.2004

akzeptiert: 29.4.2004

Publication Date:
21 July 2004 (online)

Also available at
    Permissions and Reprints

Hintergrund und Fragestellung: Ziel unserer Untersuchungen war die Bestimmung von diabetesassoziierten Autoantikörpern und ihre Beziehung zur Entstehung eines Typ 1-Diabetes bei mit Interferon therapierten Patienten mit chronischer Hepatitis C.

Patienten und Methodik: Es wurden 74 Patienten (24 Frauen, 50 Männer, Durchschnittsalter: 46 Jahre) mit chronischer Hepatitis C untersucht, die auf eine vorausgegangene Interferonmonotherapie nicht angesprochen hatten. Alle erhielten eine Kombinationstherapie aus Interferon, Ribavirin und zusätzlich Amantadin 100 mg/Tag oder Plazebo über 48 Wochen. Nach Abschluss der Therapie wurden multiple Antikörper (Anti-Insulin-Antikörper, Anti-IA-2, Anti-GAD, Anti-TPO, Anti-TG, Anti-Thyreo­tropin-Rezeptorantikörper) bestimmt.

Ergebnisse: Bei zwei Patienten fanden sich am Therapieende Antikörper gegen Inselzellantigene (GAD-Autoantikörper), jedoch waren beide negativ für IA-2 und Insulin-Antikörper. Bei einem Patienten entwickelte sich 5 Monate nach Therapiebeginn ein Typ 1-Diabetes. Der Anti-GAD-Titer des Patienten war initial bei 0 IU/ml (Norm: < 1,2) gewesen, nach der Interferonmonotherapie bei 52,2 IU/ml. Während der Interferonkombinationstherapie stieg der Titer von initial 41,1 IU/ml auf 59,6 IU/ml an. Der Anti-GAD-Titer des zweiten Patienten war 0 IU/ml vor Therapie und stieg auf 1,7 IU/ml. Ein Diabetes mellitus entwickelte sich bei diesem Patienten nicht.

Folgerung: Die Ausbildung eines Diabetes mellitus ist eine seltene, jedoch schwere Komplikation einer Interferontherapie. Wiederholte Behandlungen scheinen diese Entwicklung zu begünstigen. Die Bestimmung von Autoantikörpern gegen Inselzellantigene vor einer zweiten Behandlung könnte sinnvoll sein.

Background and objective: The aim of this study was to study the appearance of autoantibodies against islet cells and the development of type 1 diabetes in patients with chronic hepatitis C during interferon treatment.

Patients and methods: 74 patients (24 women, 50 men, mean age: 46 years) with HCV infection were treated with interferon, ribavirin and amantadin versus placebo, after they had failed to previous interferon therapy in a prospective, randomised trial. At the end of treatment period anti-islet cell autoantibodies (anti-GAD, anti IA-2), anti-insulin antibodies, TSH, anti-thyroid autoantibodies (TPO, thyreoglobulin, TSH-receptor antibodies) were measured.

Results: In two patients, GAD autoantibodies were found, but both patients were negative for IA-2 and insulin antibodies. One of the patients developed type 1 diabetes five months after start of treatment. In this patient, the anti-GAD titer was initial 0 U/ml (normal: < 1.2). The titer raised to 52,2 U/ml after the interferon monotherapy. During the second interferon treatment (in combination) the titer raised from initial 41,1 U/ml to 59,6 U/ml. The anti-GAD titer of the second patient was 0 U/ml before treatment and raised to 1,7 U/ml. This patient did not develop a type 1 diabetes.

Conclusion: Type 1 diabetes is a rare but serious complication of interferon therapy. Repetitive treatment seems to facilitate this complication. Screening for islet antibodies before a second therapy could be useful.

Literatur

  • 1 Ando H, Nagai Y, Yokoyama M, Takamura T, Kobayashi K. Antibodies to GAD in diabetic patients with chronic hepatitis C.  Diabet Med. 1998;  15 797
    Google Scholar
  • 2 Betterle C, Fabris P, Zanchetta R. et al . Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.  Diabetes Care. 2000;  23 1177-1181
    Google Scholar
  • 3 Bhatti A, McGarrity T J, Gabbay R. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.  Am J Gastroenterol. 2001;  96 604-605
    Google Scholar
  • 4 Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?.  Diabet Med. 2001;  18 329-332
    Google Scholar
  • 5 Di Cesare E, Previti M, Russo F. et al . Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis.  Dig Dis Sci. 1996;  41 1672-1677
    Google Scholar
  • 6 Durand J M. Extrahepatic manifestations of hepatitis C virus infection.  Am J Gastroenterol. 1997;  92 1402
    Google Scholar
  • 7 Eibl N, Gschwantler M, Ferenci P, Eibl M M, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha.  Eur J Gastroenterol Hepatol. 2001;  13 295-298
    Google Scholar
  • 8 El-Serag H B, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans.  Hepatology. 2002;  36 1439-1445
    Google Scholar
  • 9 El-Zayadi A R, Selim O E, Hamdy H, Dabbous H, Ahdy A, Moniem S A. Association of chronic hepatitis C infection and diabetes mellitus.  Trop Gastroenterol. 1998;  19 141-144
    Google Scholar
  • 10 Fabris P, Betterle C, Floreani A. et al . Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis.  Lancet. 1992;  340 548
    Google Scholar
  • 11 Fabris P, Betterle C, Greggio N A. et al . Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis.  J Hepatol. 1998;  28 514-517
    Google Scholar
  • 12 Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy.  Aliment Pharmacol Ther. 2003;  18 549-558
    Google Scholar
  • 13 Ferri C, Zignego A L. Relation between infection and autoimmunity in mixed cryoglobulinemia.  Curr Opin Rheumatol. 2000;  12 53-60
    Google Scholar
  • 14 Floreani A, Chiaramonte M, Greggio N A. et al . Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients.  Ital J Gastroenterol Hepatol. 1998;  30 71-76
    Google Scholar
  • 15 Hadziyannis S, Karamanos B. Diabetes mellitus and chronic hepatitis C virus infection.  Hepatology. 1999;  29 604-605
    Google Scholar
  • 16 Hadziyannis S J. Nonhepatic manifestations and combined diseases in HCV infection.  Dig Dis Sci. 1996;  41 63S-74S (Suppl 12)
    Google Scholar
  • 17 Hadziyannis S J. The spectrum of extrahepatic manifestations in hepatitis C virus infection.  J Viral Hepat. 1997;  4 9-28
    Google Scholar
  • 18 Harman-Boehm I, Zingman L, Hilzenrat N. No evidence for anti-islet autoimmunity in diabetes mellitus associated with chronic hepatitis C infection.  Hepatology. 1999;  30 342
    Google Scholar
  • 19 Hieronimus S, Fredenrich A, Tran A, Benzaken S, Fenichel P. Antibodies to GAD in chronic hepatitis C patients.  Diabetes Care. 1997;  20 1044
    Google Scholar
  • 20 Honeyman M C, Stone N L, Harrison L C. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents.  Mol Med. 1998;  4 231-239
    Google Scholar
  • 21 Imagawa A, Itoh N, Hanafusa T. et al . Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis.  J Clin Endocrinol Metab. 1995;  80 922-926
    Google Scholar
  • 22 Kado S, Miyamoto J, Komatsu N. et al . Type 1 diabetes mellitus caused by treatment with interferon-beta.  Intern Med. 2000;  39 146-149
    Google Scholar
  • 23 Mayo M J. Extrahepatic manifestations of hepatitis C infection.  Am J Med Sci. 2003;  325 135-148
    Google Scholar
  • 24 Mofredj A, Howaizi M, Grasset D. et al . Diabetes mellitus during interferon therapy for chronic viral hepatitis.  Dig Dis Sci. 2002;  47 1649-1654
    Google Scholar
  • 25 Narvaez I, Perez B, del Mar Alcalde M, Jimenez C, Soria A. Chronic viral hepatitis, interferon, diabetes mellitus, and celiac disease.  Am J Gastroenterol. 2003;  98 2336-2337
    Google Scholar
  • 26 Obermayer-Straub P, Manns M P. Hepatitis C and D, retroviruses and autoimmune manifestations.  J Autoimmun. 2001;  16 275-285
    Google Scholar
  • 27 Okanoue T, Sakamoto S, Itoh Y. et al . Side effects of high-dose interferon therapy for chronic hepatitis C.  J Hepatol. 1996;  25 283-291
    Google Scholar
  • 28 Paris R. Association of hepatitis C and diabetes mellitus.  Ann Intern Med. 2001;  135 141-142
    Google Scholar
  • 29 Piquer S, Hernandez C, Enriquez J. et al . Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon.  J Lab Clin Med. 2001;  137 38-42
    Google Scholar
  • 30 Recasens M, Aguilera E, Ampurdanes S. et al . Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C.  Diabet Med. 2001;  18 764-767
    Google Scholar
  • 31 Seifarth C, Benninger J, Bohm B O, Wiest-Ladenburger U, Hahn E G, Hensen J. Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C.  Z Gastroenterol. 1999;  37 235-239
    Google Scholar
  • 32 Tohda G, Oida K, Higashi S, Hayashi T, Miyamori I. Interferon-alpha and development of type 1 diabetes: a case without insulin resistance.  Diabetes Care. 1998;  21 1774
    Google Scholar
  • 33 Uto H, Matsuoka H, Murata M. et al . A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy.  Diabetes Res Clin Pract. 2000;  49 101-106
    Google Scholar
  • 34 Wasmuth H E, Stolte C, Geier A, Gartung C, Matern S. Induction of multiple autoantibodies to islet cell antigens during treatment with interferon alpha for chronic hepatitis C.  Gut. 2001;  49 596-597
    Google Scholar
  • 35 Wesche B, Jaeckel E, Trautwein C. et al . Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C.  Gut. 2001;  48 378-383
    Google Scholar
  • 36 Wong V, Fu A X, George J, Cheung N W. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis.  Clin Endocrinol (Oxf). 2002;  56 793-798
    Google Scholar

Dr. Marcus Schories

Innere Medizin II

Hugstetter Straße 55

79106 Freiburg

Phone: 0761/2703420

Fax: 0761/2703413

Email: schories@med1.ukl.uni-freiburg.de

      >